Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kyntra Bio (KYNB) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $4.0 million.

  • Kyntra Bio's Shares Outstanding rose 36.32% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 36.32%. This contributed to the annual value of $4.0 million for FY2024, which is 217.35% up from last year.
  • According to the latest figures from Q3 2025, Kyntra Bio's Shares Outstanding is $4.0 million, which was up 36.32% from $4.0 million recorded in Q2 2025.
  • Kyntra Bio's 5-year Shares Outstanding high stood at $98.3 million for Q3 2023, and its period low was $4.0 million during Q4 2023.
  • In the last 5 years, Kyntra Bio's Shares Outstanding had a median value of $92.6 million in 2021 and averaged $56.4 million.
  • As far as peak fluctuations go, Kyntra Bio's Shares Outstanding skyrocketed by 477.02% in 2023, and later tumbled by 9591.06% in 2024.
  • Quarter analysis of 5 years shows Kyntra Bio's Shares Outstanding stood at $92.9 million in 2021, then increased by 1.38% to $94.2 million in 2022, then crashed by 95.8% to $4.0 million in 2023, then increased by 2.17% to $4.0 million in 2024, then increased by 0.22% to $4.0 million in 2025.
  • Its Shares Outstanding stands at $4.0 million for Q3 2025, versus $4.0 million for Q2 2025 and $4.0 million for Q1 2025.